Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
14/05/2026 22:14
May 14 (Reuters) - Maia Biotechnology Inc MAIA.A: MAIA BIOTECHNOLOGY INC - TO TERMINATE AT THE MARKET OFFERING AGREEMENT EFFECTIVE MAY 23, 2026 - SEC FILING MAIA BIOTECHNOLOGY INC - SOLD 3.1 MILLION SHARES FOR GROSS PROCEEDS OF $5.7 MILLION UNDER SALES AGREEMENT - SEC FILING Source text: [ID:n0001493152-26-023168] Further company coverage: MAIA.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale